Cargando…

Immune signature of metastatic breast cancer: Identifying predictive markers of immunotherapy response

In breast cancer (BC), up to 10–20% patients were known to have clinical benefit with immune checkpoint inhibitors, and biomarkers are needed for optimal use of this multi-potential therapeutic strategy. Accordingly, we conducted an experiment to identify expression of genes associated with immune c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ji-Yeon, Lee, Eunjin, Park, Kyunghee, Park, Woong-Yang, Jung, Hae Hyun, Ahn, Jin Seok, Im, Young-Hyuck, Park, Yeon Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564574/ https://www.ncbi.nlm.nih.gov/pubmed/28537889 http://dx.doi.org/10.18632/oncotarget.17653

Ejemplares similares

The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2015)

Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lee, Soohyeon, et al.
Publicado: (2022)

Gene Expression Profiling of Breast Cancer Brain Metastasis
por: Lee, Ji Yun, et al.
Publicado: (2016)

Intra-tumoral Metastatic Double Primary Carcinoma: Synchronous Metastatic Tumor in Lung from Breast and Thyroid Carcinoma
por: Park, Lee Chun, et al.
Publicado: (2014)

Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
por: Jung, Hae Hyun, et al.
Publicado: (2016)

Real World Experience of Second-Line Treatment Strategies after Palbociclib and Letrozole: Overall Survival in Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

The Impacts of Inclusion in Clinical Trials on Outcomes among Patients with Metastatic Breast Cancer (MBC)
por: Lee, Ji Yun, et al.
Publicado: (2016)

Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer
por: Shin, Junghoon, et al.
Publicado: (2023)

Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
por: Heo, Mi Hwa, et al.
Publicado: (2019)

Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
por: Kim, Ji-Yeon, et al.
Publicado: (2021)

TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
por: Kim, Ji‐Yeon, et al.
Publicado: (2023)

Real-World Evidence of Trastuzumab, Pertuzumab, and Docetaxel Combination as a First-Line Treatment for Korean Patients with HER2-Positive Metastatic Breast Cancer
por: Lee, Yong-Pyo, et al.
Publicado: (2022)

A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: Jung, Hae Hyun, et al.
Publicado: (2023)

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
por: Lee, Jiyun, et al.
Publicado: (2021)

Elevated Level of Nerve Growth Factor (NGF) in Serum-Derived Exosomes Predicts Poor Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
por: Jung, Hae Hyun, et al.
Publicado: (2021)

Molecular characterization of patients with pathologic complete response or early failure after neoadjuvant chemotherapy for locally advanced breast cancer using next generation sequencing and nCounter assay
por: Park, Kyunghee, et al.
Publicado: (2015)

The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Lymphocyte-activating gene 3 expression in tumor cells predicts immune checkpoint inhibitor response in triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
por: Kan, Zhengyan, et al.
Publicado: (2018)

Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
por: Kim, Ji-Yeon, et al.
Publicado: (2019)

Prognostic value of ERBB4 expression in patients with triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2016)

Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer
por: Lee, Ji Yun, et al.
Publicado: (2015)

Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
por: Hur, Joon Young, et al.
Publicado: (2020)

Genomic characteristics of triple negative apocrine carcinoma: a comparison to triple negative breast cancer
por: Kim, Ji-Yeon, et al.
Publicado: (2023)

The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
por: Lee, Kyoungmin, et al.
Publicado: (2021)

Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
por: Yi, Seong Yoon, et al.
Publicado: (2010)

Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
por: Sim, Sung Hoon, et al.
Publicado: (2019)

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer
por: Yoo, Changhoon, et al.
Publicado: (2016)

Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
por: Kim, Nalee, et al.
Publicado: (2023)

Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
por: Hong, Joohyun, et al.
Publicado: (2021)

Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
por: Kim, Hee Kyung, et al.
Publicado: (2019)

Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results
por: Park, Yeon Hee, et al.
Publicado: (2017)

Cytokine profiling in serum-derived exosomes isolated by different methods
por: Jung, Hae Hyun, et al.
Publicado: (2020)

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study
por: Lee, Su Jin, et al.
Publicado: (2015)

Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study
por: Kim, Se Hyun, et al.
Publicado: (2016)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7tq893ctel6rc2ai9ua1emh75v